NEW YORK – Fujirebio announced on Thursday that it is acquiring neurodegenerative disease diagnostic company ADx NeuroSciences for EUR40 million ($42.1 million).
The deal is expected to close in July, and Belgium-based ADx NeuroSciences will become a wholly owned subsidiary of Fujirebio Europe.
The acquisition will allow Fujirebio to “expand its antibody supply business and contract development and manufacturing offerings in the neurodegenerative field to our partners globally,” Fujirebio President and CEO Goki Ishikawa said in a statement.
ADx NeuroSciences offers antibodies and develops assays for pharma and in vitro diagnostic companies to detect neurodegenerative diseases. Its pipeline currently includes multiple phospho-tau specific antibodies for plasma as well as biomarkers targeting synaptic degeneration to help with prognosis of neurodegenerative diseases like Alzheimer’s and Parkinson’s, Fujirebio said in a statement.